ClinicalTrials.gg
CompletedNCT01652664Updated Jul 23, 2015Results posted

Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients

A Phase 3 interventional study of Travoprost 0.004% PQ ophthalmic solution and Timolol, 0.5% or 0.25% ophthalmic solution in Pediatric Glaucoma, Elevated IOP in Pediatric Patients and Ocular Hypertension in Pediatric Patients, sponsored by Alcon Research. Completed. Open to participants aged 2 Months to 17 Years. Per ClinicalTrials.gov, last updated 2015-07-23.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
2 Months to 17 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma patients.

02

Conditions studied

  • Pediatric Glaucoma
  • Elevated IOP in Pediatric Patients
  • Ocular Hypertension in Pediatric Patients

Browse trials for

03

In context

Hydrophthalmos

37 studies on the registry are indexed under Hydrophthalmos; 3 are open to participants now.

This study's enrollment of 184 is above the median of 37 across 29 interventional studies indexed under Hydrophthalmos.

Browse Hydrophthalmos studies →

Lead sponsor

Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.

Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of pediatric glaucoma or ocular hypertension.
  • Qualifying mean IOP at the Eligibility Visit in at least one eye.
  • Written , including assent when applicable, MUST be obtained from the parent or legally authorized representative prior to any procedure specified in the protocol, including screening procedures.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Females of who are pregnant, intend to become pregnant during the study period, breast feeding, or not using any form of measures.
  • History of chronic, recurrent or severe inflammatory eye disease.
  • Ocular trauma requiring medical attention within the past 3 months prior to the Screening Visit.
  • Ocular infection or ocular inflammation within the past 30 days prior to the Screening Visit.
  • or progressive retinal disease.
  • Severe ocular pathology (including severe dry eye) that, in the opinion of the Investigator, would preclude the administration of a topical prostaglandin analog or a topical beta-blocker.
  • Intraocular surgery in the study eye within 30 days prior to the Screening Visit.
  • Any abnormality preventing reliable applanation tonometry.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    Travoprost

    Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months

    Drug: Travoprost 0.004% PQ ophthalmic solution · Drug: Travoprost Vehicle

  • Active comparator
    Timolol

    Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months

    Drug: Timolol, 0.5% or 0.25% ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in IOP at Month 3

    IOP (fluid pressure inside the eye) was assessed using a calibrated tonometer and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye from each participant was chosen as the study eye and only the study eye was used for analysis.

    Time frame: Baseline (Day 0), Month 3

07

Results

Posted Apr 13, 2015

Participant flow

Participants were recruited from 38 investigational centers in the United States, Germany, Singapore, United Kingdom, Taiwan, Philippines, Spain, Saudi Arabia, Colombia, France, Portugal, Belgium, Poland, Romania, Puerto Rico, and Mexico.

Participant flow — Overall Study
MilestoneTravoprostTimolol
Started7775
Completed7174
Not completed61
Withdrew: Treatment failure51
Withdrew: Inadequate iop control10

Outcome measures

PrimaryMean Change From Baseline in IOP at Month 3

IOP (fluid pressure inside the eye) was assessed using a calibrated tonometer and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye from each participant was chosen as the study eye and only the study eye was used for analysis.

Time frame:
Baseline (Day 0), Month 3
Reported as:
Mean · mmHg
Mean Change From Baseline in IOP at Month 3
mmHgTravoprostTimolol
Mean Change From Baseline in IOP at Month 3-5.4 ± 0.98-5.3 ± 0.93

Adverse events

Collected over Adverse events (AEs) were collected for the duration of the study (05 Sep 2012 - 25 Mar 2014). This analysis group includes all enrolled participants.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pre-Treatment—0/184 (0%)1/184 (0.5%)
Travoprost—0/77 (0%)22/77 (28.6%)
Timolol—2/75 (2.7%)6/75 (8%)
Most frequent serious events
Most frequent serious events
EventPre-TreatmentTravoprostTimolol
Keratitis bacterialInfections and infestations0/1840/771/75
PneumoniaInfections and infestations0/1840/771/75
Viral infectionInfections and infestations0/1840/771/75
Most frequent other events
Most frequent other events
EventPre-TreatmentTravoprostTimolol
Ocular hyperaemiaEye disorders0/18415/773/75
Growth of eyelashesEye disorders0/1845/770/75
HeadacheNervous system disorders1/1845/772/75
Conjunctival hyperaemiaEye disorders0/1844/771/75

Baseline characteristics

This analysis population includes all participants who received study drug and completed at least 1 scheduled on-therapy visit.

Age, Customized
Age, Customized(participants)TravoprostTimololTotal
2 months to <3 years10616
3 to <12 years403979
12 to <18 years273057
Sex: Female, Male
Sex: Female, Male(Participants)TravoprostTimololTotal
Female404080
Male373572
Intraocular Pressure
Intraocular Pressure(mmHg)TravoprostTimololTotal
Mean24.7 ± 4.6224.2 ± 4.0124.4 ± 4.32
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2012
First posted
Jul 30, 2012
Start
Sep 2012
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results first posted
Apr 13, 2015
Last update
Jul 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01652664
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Jul 30, 2012
Start date
Sep 2012
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Apr 13, 2015
Last update
Jul 23, 2015

Study contacts

Subha Venkataraman, Clinical Project Lead
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion